Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7600711

Fibrel.

M H Gold
View original source ↗Export metadata ↓

Abstract

Fibrel is a useful product for the treatment of depressed cutaneous scars, facial lines, and wrinkles. There have been documented increases in collagen production and inflammatory response over time. Adverse reactions seem to be minimal. If a more user-friendly product can be used--no plasma, minimal inflammatory response, 30-gauge needle--Fibrel should be considered in all patients for soft tissue augmentation.

Explore related subjects

AminocaproatesAnimalsCollagenGelatinHumansInjections, SubcutaneousSkinSkin DiseasesSurgery, PlasticJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M H Gold. 1995. Fibrel.. https://pubmed.ncbi.nlm.nih.gov/7600711/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins.

Ascorbate (vitamin C) degradation products can undergo non-enzymatic glycation (Maillard reaction) with proteins to form highly crosslinked structures with brown pigmentation and characteristic fluorescence. Proteins in the body, especially the long-lived proteins develop similar changes during aging and diabetes. Several studies have shown excessive degradation of ascorbate in plasma in diabetes, and in ocular lens during aging and cataract formation. Recent studies have suggested that ascorbate degradation products-mediated glycation plays a role in lens pigmentation and cataract formation. However, the precise chemical nature of ascorbate-specific advanced glycation end-products are not known. Here, we report the purification and characterization of a glycation end-product derived from one of the major degradation products of ascorbate, L-threose. This compound was characterized to be 2-acetamido-6-(3-(1,2-dihydroxyethyl)-2-formyl-4-hydroxymethyl-1- pyrrolyl)hexanoic acid (formyl threosyl pyrrole or FTP) formed by the condensation of epsilon-amino group of lysine with two molecules of threose. Formation of FTP occurred rapidly in the incubation of threose and lysine and reached plateau level within a day. We have developed a sensitive assay for its quantification in proteins based on enzyme digestion followed by HPLC. Ribonuclease A and human lens crystallins incubated with L-threose showed time- and sugar concentration-dependent increases in FTP, reaching 8.2 and 2.48 nmol per mg protein, respectively after one week of incubation. Human plasma proteins showed a peak with identical retention time as that of purified FTP under two different HPLC conditions. FTP may be used as a sensitive marker to assess ascorbate-mediated protein glycation and modifications in aging and diabetes.

Aminocaproates↗
PubMed1995

Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B.

Concomitant use of the monoclonal antibody-purified factor IX concentrate (Mononine, Armour Pharmaceutical Company, Collegeville, Pa.) and two antifibrinolytic agents, epsilon-aminocaproic acid (EACA; Amicar, Immunex, Seattle, Wash.) or tranexamic acid (AMCA; Cyklokapron, Kabi Pharmacia, Piscataway, N.J.) was examined for safety and efficacy in patients with hemophilia B. In a retrospective review of 19 patients treated with monoclonal antibody-purified factor IX and EACA on 35 occasions, bleeding was successfully controlled and no instances of clinical thrombotic complications were reported; one instance of urticaria resolved without additional treatment. The use of EACA or AMCA in combination with monoclonal antibody-purified factor IX was also examined prospectively in a study of 9 patients. Bleeding was effectively controlled and no thrombotic events were detected clinically with either antifibrinolytic agent. No significant changes in hematocrit or hemoglobin were detected, and there was no evidence of thrombosis as evaluated clinically and by sensitive molecular markers. It was concluded from both the retrospective and prospective data that monoclonal antibody-purified factor IX concentrate in combination with an antifibrinolytic agent does not activate the coagulation cascade and is a safe and effective treatment for prevention and control of oral bleeding in hemophilia B patients.

Aminocaproates↗
PubMed1995

[Pharmacokinetics of zinc acexamate (ZAC) in rats].

Zinc acexamate (ZAC) is a new antiulcer drug. This paper reports the pharmacokinetics of ZAC in rats after single oral administration. The concentrations in biological samples were detected by spectrophotometry. This study shows that the concentration-time curve of ZAC in blood conformed to a single-compartment open model after 250, 500 and 750 ng.kg-1 ig. ZAC absorption was fast and the peak plasma level appeared in 1.5 h. The Cmax, AUC and CL/F were shown to be dose dependent. Two hours after oral administration of ZAC to normal rats, the highest level of ZAC was present in the gastrointestinal tract, while appreciable ZAC was present in the kidney, liver, plasma and lung. The level of ZAC in heart, spleen and brain was lower, no drug was detected in muscles and uterus. Six hours after oral administration, the drug concentration in various tissues decreased rapidly, but that of the gastrointestinal decreased very slowly. Feces excretion was an important route of excretion. ZAC excretion was about 11.7% of the administered dosage in feces within 48 h period, and the excreted amount from urine and bile was very small.

Aminocaproates↗